Quarterly report pursuant to Section 13 or 15(d)

DEFINITE-LIFE INTANGIBLE ASSETS

DEFINITE-LIFE INTANGIBLE ASSETS	9 Months Ended
Sep. 30, 2014
DEFINITE-LIFE INTANGIBLE ASSETS
DEFINITE-LIFE INTANGIBLE ASSETS	NOTE 4 - DEFINITE-LIFE INTANGIBLE ASSETS The Company’s definite-life intangible assets are amortized, upon being placed in service, over the estimated useful lives of the assets, with no residual value. There was no amortization expense for the nine months ended September 30, 2014 and 2013. As of September 30, 2013, the Company’s management decided to take an impairment charge of $6,234 representing the unamortized basis of the patents related to the creation and production of its product, ProAlgaZyme which is no longer producing revenue. The write off of the impairment loss was included in General and Administrative Expenses on the Statement of Operations for the nine months ended September 30, 2013.

DEFINITE-LIFE INTANGIBLE ASSETS

9 Months Ended

Sep. 30, 2014

NOTE 4 - DEFINITE-LIFE INTANGIBLE ASSETS

The Company’s definite-life intangible assets are amortized, upon being placed in service, over the estimated useful lives of the assets, with no residual value. There was no amortization expense for the nine months ended September 30, 2014 and 2013. As of September 30, 2013, the Company’s management decided to take an impairment charge of $6,234 representing the unamortized basis of the patents related to the creation and production of its product, ProAlgaZyme which is no longer producing revenue. The write off of the impairment loss was included in General and Administrative Expenses on the Statement of Operations for the nine months ended September 30, 2013.